ｱﾝﾌﾞﾛｷｿｰﾙ溶出量(μg)
Contents
1.2.
3.
4.
5. 2011 PC2006 161 2
6. 72 7 1 10 50 1
7. AVE
8. 2007 wiki
9. 15 ZAK ZO 2011 PC2006 126 DPE 4
10. 8 DERIOE Wick E 2011 PC2006 051 Wi Jy 5 Resveratrol Resveratrol 7gzs 3 5 4 trihydroxystilbene
11. yyo in vivo 20 FH BE 6 in vivo 11 2 13 Skg 3 1 0mg kg EAB SU WIV 4ml Gv 0 1mg k
12. 2011 PC2006 166 SX 2 Epithhial Epithelial
13. DV 2008 701 26 5 2 Cohen et al Drug and Alcohol Dependence 2007 vol 86 P214 221 26 2011 PC2006 060 f PF BTS Em col F 7 0 gt DVOME TY
14. 19
15. H ABNEY 5 6 026 FE 2
16. 36 47 06 RUF RAUL EWC
17. 2011 PC2006 090 GI 1
18. A Randomized Trial of Low Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women N Engl J Med 2005 352 1293 304 Excel 2 t RR 95 CI p LAs table1 Body mass index
19. A School Based Intervention for Diabetes Risk Reduction Engl J Med 2010 363 1769 1770 October 28 2010 7 42 4603 2 21 BWEAAMO 2117 FX 21 6 8 BMI
20. 2 2011 PC2006 020 Nocaldia farcinica W farcinica E farcinica
21. 4 HDF Ve YATRA E 40mg kg 6 12 cnt 1 18 2 ik 24
22. 7 78 71 309 1 5 63
23. NR NR NR ax 2011 gt PC2006 129
24. 2011 PC2006 168 1 ce 4 E
25. 1 2 6 7 80 1 12 20 21 2
26. FOS ol rest 3 E FOS 4 1 7 8 C FOS CF
27. KE 1 5 277 1 5 BE 31 20 3 602 B fluorou
28. ICU
29. PC2006 015 HDAC GABAA GABAA 9 HDAOC
30. il 0 25mL 2M 101 50 1 4mL 10 HPLC 8M NaOH 100 1 6mL 10 SmL 0 251 HPLC HPLC
31. Yo
32. PC2006 087 DIHS DIHS Stevens Johnson lt gt Ti E TEN 1 DIHS STAGE CiNi
33. pH 3 8 Briton Robinson lg gmL 60 2 pH pHS 6 40C 3 HPLC 25mMNaH PO 25mMNaHPO pH7 5
34. FE 60 2 EX ZF 85 20 20
35. WF BP HP DI Tf Ii
36. ei ei 2 5 Ds H 1 x 2 3
37. EAE Table1 1 56 AAR OD 2 3 E 1 20 2 H A H ON Table1 RO SW
38. 2011 PC2006 089 Resveratrol Resveratrol gzs 3 5 4 trihydroxystilbene Resveratrol Resveratrol wo
39. 2009 11 24 13 4 22 1 223 6 3 3 PC2006 047
40. 6 0 3 4 PC2006 131 3 1 1 8 NE
41. in vitro GFP mRNA SH mRNA SH mRNA DHFR PURESYSTEM SH DHFR mRNA lt go mRNA PURESYSTEM 6
42. Bangham SUV Bangham Preparation of liposomes using an improved supercritical reverse phase evaporation method Langmuir 2006 22 2543 2550 2011 PC2006 039 6
43. TAP nt Io 1 Efflux Pump Contribution to Multidrug Resistance in Clinical Isolates of Pseudomonas aeruginosa Journal of Antimicrobial Chemotherapy 60 132 135 2010 2 A highly carbapenem resistant Pseudomonas aeruginosa isolate with a novel blayiy_ blap integron overexpresses two efflux pumps and lacks OprD Pharmacotherapy 30 632 638 2010 2011 PC2006 136 MacAB TolC 1 5 SANS
44. ISCRPRE Ai Luros to B16 ul MTS ASSAY 0 2 LH ASSAY Ai Luros Ai Luros 2wt 10wt 2008 242296 A
45. in vivo 3mg kg FNA
46. DPP 4 SU 47 33 37 2011 PRIX 53 505 508 2010 2011 PC2006 162
47. Steering Committee of the Physicians Health Study Research Group Final report on the aspirin component of the ongoing Physicians Health Study N Engl J Med 1989 321 3 129 35 PC2006 213 Ef A EZ OTC
48. Bre Passive 4 89 0 1mA OF BHT gt 202 0 1 1 5 Bt unl 76 0 3mA RR 68 D E
49. 2 AIEEE 5 ZUNE Smoking Smoking Cessation and Risk for Type 2 Diabetes Mellitus Ann Intern Med 2010 152 10 17 Excel 1 JMP SPSS E BE
50. 128 319
51. 3 2011 PC2006 184 A A EAR LTE PRE 1 24
52. La 4 6 FX 1 ER DOF IH 1 IFN E ALT 176 35 AST 155 45 11 17 2 RRR 201
53. 2011 A PC2006 030 gt Morinda citorifolia L 1 PE Ae rutin LTH 1 535 1 2 Mcitorifolia noni prostaglandin PG
54. 22 1 1 LP 24 HP LP 1 0 5 0 HP 1 Ww IF F 28 4
55. o OTIPS Elisapterosin B Elisabethin C 2011 PC2006 199 Pd C 0 0 100mg CHaOH 10 Pd C 20mg K CO 500mg 3 O 10 Pd C 8 77 R
56. 2 9 EE 20 2 HH 2011 1 16 24 9 3 6 3 18 1 4 9 17 3 E 9 2
57. FE 22 11 28 MTEL ER 6 116 MVD 75 2 9
58. HH M1 HH FE 8 NADPH H 7 4 37C 1 0 mM 530 uM 10 20 HPLC M1 HH
59. Fig 1 Hig 2 BH eb i
60. Av 5 EAN PS WE 25 15
61. 4 5 1 NMM 7 44 10 20 THY 7
62. 2011 PC2006 149 22 10 65 23 1 18 4 E 33 37 48
63. PGE Hist M citrifolia specimen No SKP010002T McL2 300 MeOH 31 2 g MeOH CH HP20 CO fr 2C 0 93 g 2 10 1 gmL PGE Hist fr2C Sephadex LH 20 CC CHCL MeOH 1 3 fr4A 4D 1 X10 5 g mL fr4A fr 4B PGE HHst fr4A fr4B fr4C fr 4B ODS TLC
64. mn to tc ZT 005 13311 4 2 HHHG 3 5 5 0000 DHFROF 7 AAR ERS Ps gt 6 8H A 6 lt JSP 0 0 FF SS NN S 8 WW 8 Shingaki 7 and Nimura N Protein Expr Purif 77 2 193 197 2011 2011 EF PC2006 203 EK
65. 1 1 2 4 ni MR ER ANH 4 EEX 0 56 SAIN h 1 3 fe
66. FEE PC2006 012 APY c di GMP 04 cyclic di GMP c di GMP c di GMP c di GMP GGDEF EAL YfeA
67. FOS Ohta A etal J Nutr 128 485 490 1998 2011 PC2006 064 citrus depressa JA Hi FE 6 7
68. 2 PC2006 045 5 E 1 1 3 1 AME AUD 500 CO C 8 AUC 2 lt 1 0 CO 1 1 0
69. Post epithelal 3 Dl 1H Pre epithelial Epithelial EB SD
70. 95 144 1 20 PEG 1000 0 2 M Ca OAc pH 7 0 7 5 4 als l Hoshino Y et al 1 Antibiot Tokyo 2010 Vol 63 1 8 0 2 0 4 mm BL NE3A E 2011 3 gt PC2006 023 NDM 1 8
71. Cmax 1 10 Cmax in vitro 7 7 SKIN CAD invivo 1l vitro vitro in vivo in vitro yyo HE ICmax ngimD 8 02 4 03 12 5143 73 5 2040 69 _ S E n 3 Cmax
72. 1 DPB COPD 14 messenger RNA HeLa RPMI CAM 55 gu g ml 10 80 Hh 30cm CAM 72 SDS PAGE LPS A549 DMEM EMA 50g g ml RXM 25 g ml 150cm 2 72 EBNF micro RNA 2 AE SF2 A
73. RE LZ FER x103 RRR EAD 0 LL AB 0 002 0 01 f BCG EX 2 0 01
74. 1995 4 BN 02 ETRE 1 E 60 1 40 2000 81 2 1 F 35 gt 105
75. TRE AMARANTE HE 128
76. 3 5 URL http www info pmda go p shinyaku_index html Accessed 2010 July 4 2011 8 PC2006 088 K 4 NE KN i AiR 0 RIN A HE E 2009 11 24 7
77. 2 t 95 271 50 26 1 26 0 0 1 0 048 0 00086 0 19914 19934 19942 SRE 5 1 5 0 5 1 4 BMT 0 05 t BMI 2 0 1 2 2
78. Adipose tissue derived stromal cells ADSC Ha 9 5 8 SSV BADR Li Wen SSVLYGGPPSAA DA SSV SSV H1 LPQ LT E FUE SSV SSV 7 LPQ
79. EX p 0 043 35 Ex Sed Ex CD Ex CT 60 Ex CD pH BE Ex CT 45 0
80. SGs SGs mRNA RNA 40S SGs SGs mRNP SGs SGs mRNA 5 UTR terminal oligo pyrimidine TOP 3 3 UTR AUUUA AUF1 A U rich binding factor1 SGs AUF1 AUF1 SGs RPM
81. E 2009 6 7 60 30 16 7 Ee 38 8 8 7 MAAN 7 389685 9 5 6
82. Supercritical reverse phase evaporation SCRPE 2 tro Resveratrol 1X105 well Resveratrol 48 490nm 3 Resveratrol Resveratrol 1 1
83. URL http www info pmda so jp shinyaku_index html Accessed 2010 June 10 2011 8 RR HASNT 2009 1 LARA BRE LU 3 Mons 44 8 URL http www info pmda go jp shinyaku_index html RS
84. ddY 38 95 0s 5 CO gt ddY 15 2cm 2mgykg 3mg kg 8 B FNA 40mg kg 15 15 24
85. MCLWGPGRK p PURESYSTEM D D D PURESYSTEM D 2011 6
86. Bangham A 2 el Bangham UTE Bangham 5 7 oer 54 Rin Ab 2 2 Bangham 4 2 3 4 9 ERPAAZRTC Bangham
87. FICA 1 fluoroindan l carboxylic acid PF H NMR FICA NMR PMP SR FICA NMR 4 Me FICA S Me FICA S5 Me FICA Me ester 4 Me FICA Me ester 5 methyl 1 indanone Wittig
88. 2 9 InBed Time 0 29 0 54 0 39 0 56 atency 3 9 22 5 4 27 Efficiency 88 9 4 87 1 1 Total Sleep Time 3266 661 308 7 616 Wake After Sleep Onset 34 5 10 38 9 180 Average Awakening Length 29 5 34 2 2011 PC2006 116 EE 13 YONIRNRE es 24 1
89. IBS transient receptor potential vanilloid type1 TRPV1 5 HTs 4 1BS AEs SD 3 20 80mmHg
90. PMDA PMDA 3 URL http www info pmda so jp shinyaku_index html Accessed 2010 June 10 2011 PC2006 084 FAFA
91. Fig OVE 2 cort 2011 EE PC2006 170 4 GP GF 8 DZP FUE EVER DHA
92. 2011 pc2006 022 2 2 4 ANE FT RA An xt 2 FA nn Study FR i 51 0 Ha FA Excel gt AE H 2X 4 P
93. EX cl ass SHR 4 p SHR NN
94. 12000rpm FED FOS DE AIN 93G C CE D DE 2 3 10 pH pH TWINpH C CF D DF
95. 31 35 36 2009 ISBN 0919 2131 2011 PC2006 164 c di GMP yegE iE O PCR A cyclic di GMP c di GMP c di GMP GGDEF c di GMP c di GMP c di GMP EAL c di GM
96. Epithelial TRPA1 DAMN AA 2011 PC2006 172 H
97. 4
98. EFEX WMT AFA HP TAZ 21 20 2 8 5
99. TMRM i 3 i 1 51 SDS PAGE CBB ee Shay RYVTEEN OME fraction1 0 30 fraction2 30 80 SDS PAGE fraction2 10 um fraction2 3 Yehicle fraction1 fraction2 FG a a mas Na QO 1 6 2 hs oq 6 Ol 2 4 2 4 5 A 43 A 5 RE 4 ta 20190 2 Kav RY FH control TMRM fraction2 ROS
100. in vivo 1 Z Ge E Tessier etc Journal of Chromatography B 806 2004 299 303 2 MJ Nosal etc Journal of Pharmaceutical and Biomedical Analysis 30 2002 285 291 2011 PC2006 147 5 Invitro BEI In vitro FT FET FE FmL hy 6 Tw Cw
101. 6 3 An Oral Spleen Tyrosine Kinase Syk Inhibitor for Rheumatoid Arthritis Engl J Med 2010 363 1303 1312 September 30 2010 gt t x 2 gt 100mg 5 8 R788 150mg1
102. 7 6 E 6 E 2 i 2
103. 1 1 3 2 EN E EEO AND E 2011 PC2006 096 EPA DHA FFA 06 5 57
104. 19804 4 19904 a gx 475 0 4 Fig 2 5 5 0 4 erin o 2 0 oo ro 2 2 5 5 5 5 555 oe 10 0 FC EE DATA 2 00 5 E Fig DEES ETE EF URL http www mhlw so jp touke list 32 19 html 6 http ganjoho jp professionalindex html
105. 6 0 7 0 1 Reboxetine for acute treatment of major depression systematic review and meta analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials BMJ 2010 341 c4737
106. TAZ PIPC 1 8 8 TAZPIPC 1 8 CADE EMAAR EAE IHX dD 2 3 F 8
107. 2 1982 2010 39 aisTslisTsTc1 SSSSS amp SSSSSSSSSS x esc alale 5 L 9 1 2 5 2 5 5 5 5 2 8 5 5 5 5 5 2 5 8 11 800 2 0 02 61 209 0 1 987 568 5 0 0003 8 0 0001 40 0 004 2011 LEZ AMT ARBAB 2 as 1 3 PC2006 109 ROS
108. REN URL http www info pmda go jp shinyaku_index html 5 22 6 10 2011 PC2006 1 04 4 I 1 1 423 1 5 36 1 MTD
109. 1 WF CDA chiral derivatizing REE CDA FICA 1 fluoroindan 1 carboxylic acid BR BO EG AB TR NMR NE Sl ro nex oc Ph3PMeBr Os IC1 PC HO Br MeOH alcohol F eS lt COOMe Bul gt Br Br 5 Br FICA 5 Br FICA ore cts ctl 1 ae oe ans lie eet 21727 H NMR SF NMR CDA
110. 2011 REE PC2006 038 gt iA RAAT 23 1 EOE 1967 1977 0 4 4 3 4 MESA SDE 1 1989 4 rs 2 E
111. f E ddY 1 REECE FITC 1 1 n CHAT 5 HT FITC TRITC 2 1 gt NO nNOS 06 OLYMPUS FV1000 FITC 2
112. CDC EE
113. 1 E CoQ10 CoQ10 FACS CoQ10
114. E PMDA 1 lA 62 PMDA 3
115. TRPV1 yx Transient Receptor Potencial Vanilloid 1 TRPV1 ECA LES GERD TRPV1 LES TRPV1 GERD TRPV1 GERD GERD
116. 170 GEP MacB MacB REDE GFP MacB
117. 143 91 51 42 36 40 24 47 70 2 46 1 43 38 13 1 1 2 6 7 1 20 21 25 74 72 28 58 19 80
118. Zn Zn Zn Zn 12 Zn d7 d11 3 Zn C HSD CZ Zn
119. vitro 1 389 340 2009 2011 PC2006 174
120. Mg Mg Mg Mg 10kHz Mg 5 Mg Mg ee ae aoe Ren 5 Jcl SD 20 Mg 15
121. 12 TAZ PIPC 1 4 8 E co7 2 97 99 TAZ PIPC 1 4 91 8 Lr 1 4 58 5 1 29 102 2010 2011 PC2006 006
122. 3 7 3 3 MBE 3
123. TRPA1 2011 5
124. 2011 PC2006 197 3 AA THA 3 5 08 ye 205 5 8 E 79 120
125. 0 menthol PhsPCl Ph2PCl 1 5 PhsPC1 1 BulLi BulLi EtsN or Buli Buli Et3N r t 80C rh r t rh r t 38 17 trace trace 22 29 ee 17 R 14 W 29 R AW CH3 OH HaC CH l Menthol R R TADDOL PC2006 117
126. 1044 OF OTC Hm OTC 62 8 OTC 8 8 OTC 1 2 OTC EAR OTC
127. Antimicrob Agents Chemother 2009 Vol p 5046 5054 2011 PC2006 095 MRSA 8 MRSA Methicillin resistant SStaphylococeus aureus MRSA 1 vancomycin VCM arbekacin ABK teicoplanin TEIC linezolid LSD MRSA MRSA 8 8B MRSA MRSA VCM 8B
128. VA8 BA PA 5 BMJ 2010 341 c4675 doi 10 1136 bmj c4675 Published 16 September 2010 Effects of glucosamine chondroitin or placebo in patients with osteoarthritis of hip or knee network meta analysis es 1 A B 2 B C 2 B C B A C 14 8
129. Resveratrol an original mechanism on tyrosinase inhibition International Journal of Cosmetic Science 22 219 226 2000 2 Tomohiro Imura Toshihiro Gotoh Katsuto Otake Satoshi Yoda Yoshihiro Takebayashi Shoko Yokoyama Hitoshi Takebayashi Hideki Sakai Makoto Yuasa and Masahiko Abe Control of Physicochemical Properties of Liposomes Using a Supercritical Reverse Phase Evaporation Method Langmuir 19 2021 2025 2003 8 2008 242296 2011 PC2006 139 2 OEE HN E 1 vitro T 1 INTE CARB
130. ke 0
131. 0 14 0 39 Sea 2 600 7 26 6 1 7 ml kg 3 1 LA2 mM 6563 E29 7 814 2 28 5 1 E PA CE EPA 2 8 1 EPA 2 5 1 EPA mol 1 24 0 300 3 39 0 240 2 531mol EPA AA 0 08 49 9 1 88 1 3
132. GE FED 2 GE Cmax AUC 100 80 125 AE GE GE 1 GE GE 1 BONS 90 nl GE GE H
133. HH 0 PC2006 079 HHHHH HHHHHHHH HHHHH jHHHHBsHHHHHHHHHHHHHHHHH HHHHUHUHHHHHHHHHHHHHHHHHHHHHUHUHHHHHHHHHH HHHHHUHHHHHHHHHHUHUHUHHHHHHHHHHHHHHHHHHHH BslHHUHUHUHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHUHUHHUHUHHHHHHHHHHHHHHHHHH HHHHHHHHHHUHHUHHHHHHHHHHHHHUHUHHHHHHHHHHHHL HHHHHHHBsHHHHHHHHHHHHHHHHHHHUHHHH BsHHHH HHHHHUHHUHHHHHHHHHHHHHHHHHHHHHHHHH 5 HHHHHH23H3HHHHHHHHHHHHHHHHHHHHH BsHHHHH HHHHHUHHHHHHHHHHHHHHHHHHHHHHHHHU 50HHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHH HHHHHHHHHHHHHHHHHUHHHHHHUHHHHHHHHHHHHHH HHHHHUHHUHHHHHHHHHHHHHHHHHH50OHX100HHHHHH HHHHHHHHHHHHHHHHH SHH HHHHH2HH HHHHH 5 HH HHHHH SHH IHH20HHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHBsHHHHHHHHUHHUHUHUHHHHHHHHH 32 HHHHHUHHHHHHHHHHHHHHHHHHHHHH HHHHUHUHHHHHHHHH28HHH22HHHHHHHHHHHHHHHHH 43 86 HHHHHH HHH36HHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHH BsHHHHHHHHHHHHHHHH HHHHUHUHHHHHHHHHHHHHHHI 9 8 HHHHHHHHBsHHHHHHHHUHUHUHHHHHHHHHBsHHHHHHL HHHHHHHHHHHHHHHHH HHHHHH UIHHHHHHHHHHH HHHHHUHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHUHHUHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH ooo BsHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHH HHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHH
134. 1 2 3 1 F 4 JI 4 JI 10mL 4 5mL 5 5mL 4 5 4 DEK 5 5mL 5mL RAED 5mL 10mL 100mL
135. 58 15s y eg 3kb yegE TOPO TOPO yeg EcoRl Xbal cgl yegZ DNA yegE TOPO yegE pTrc99A plTrc99A G2060 TOPO yeg Ecol Xbal Smal pTrc99A pTrc99AG206 EcoRl Xbal y eg TOPO 3318bp 3500bp DNA Smal reg 3318bp y egZ p
136. GE GE E GE se GVP 0
137. 0 2 Fe HE Excel Bm AK ii mn 10 Sa 85 BY 3 incident rate A Cohort AAR EERE XAOS Ae UTE 3
138. IL 8 AI MexAB OprM Jas 36 AI AZI AZI MexAB OprM So NCBI AT DPB 7 AI E QS DOA FR HERO BY zi DPB ES QS H
139. A Ej 2010 IN 2011 PC2006 074 K Henry Henry Henry Henry RI
140. GT 0 1 11 as 4 8 5 6 7 lt 0 20 40 60 80 100
141. E RB COE URL Minds http minds jcqhc or jp stc 0028 1 0028_G0O000070_GL html http www e stat so jp SGI estat eStatTopPortal do 8OJD D 2 41 8 9 8 5 ied 40 nas 2 0 aes oe hah ee NO 6
142. TSA TSA GABAAe1 TSA GABAAc 1 GABAAc 1 TSA GABAAe 1 TSA GABAAc1 ei HDAC GABAAo 1 HDAC
143. 0 27 0 44 48 9 0TC 79 5 20 59 80 OTC 30 OTC
144. 4 E FCB E 1 2011 PC2006 130
145. ASAD 10 30mg kg WistarHannover 150 260 g 8 00 20 00 1 1 30mg kg 1 H EST Forced swim test
146. FE 5HT ei 3 AF
147. LRSA 26 Madqrid 1000 15 6 5 ICU TH 2 LRSA PCR cr 5 V nested PCR Cr BY V iF il ES 2000 5 1 UX ee al Madrid CO LRSA
148. Hajos Parrisch 1a Wieland Miescher 1b 1 8a b lab NN 3a b 3a b 2a b 9 1 2 3 4
149. in vitro Resveratrol Resveratrol in vitro B16 Resveratrol MTS Resveratrol B16 MTS Resveratrol Resveratrol 2wt v 10wt v 20wt v 3 Resveratrol Resveratrol Resveratrol 10w v
150. DPP 4 FER AE ERB DZ UAE LTE R 65 FAX EAX
151. 8 TAZ PIPC 1 8 17 7 1 Xl TIE RSET 47 46 APIA AHI 6 96 2 3 pp 40 TAZPIPC 1 8 7 5 4 3 5
152. 2 0 lll 3 5 2 7 5 0 4 5 6 0 1 F lt 1
153. 1 1 AED 1 2 2010 7 A 5 IE 1 MTD MAD 13 4 22 7 223
154. Bi D D 15g 3 4 4 22 1 3 4 3 4 10cm 4cm lcm
155. AN pGEM T easy web http clustalw ddbj nig ac jp top html http searchlauncher bcm tmc edu seq util Options sixframe html CDR Zs lt CDR OH Kabat Chothia 2 CDR 1 Kabat Chothia 5 Kabat Chothia E CDR 24
156. 0TC OTC 3 a iC 2011 PC2006 177 cy 1 A 3H 5 0
157. 1 X100 33 57 Bathe 2 ee OO es 2 2 0 8 67 24 uEq hr 8 0 1 30 mg kg s c 10 0 1 mg kg s c
158. FDA 4 E 2000 182 TABLE 2 Odds ratio for any cardiopulmonary event occurring during influenza season among women aged 15 44 years enrolled in the Tennessee Medicaid program by pregnancy status 1974 1993 status Postpartum Nonpregnant Week 1 7 Week 8 13 Week 14 20 Week 21 26 Week 27 31 Week 32 36 Week 37 42 Prevalence Cases n 4 369 n 21 845 44 866 ORt 1 11 1 06 123 144 252 262 3 21 95 Cit 0 94 1 32 0 68 1 67 0 79 1 93 0 97 2 15 1 74 3 65 1 82 3 76 2 32 4 44 3 42 6 39 Odds ratios were adjusted for all factors listed in table 3 OR odds ratio Cl confidence i 47 gt lt Referent 34 5 4 0 URL ADT Printed in U S A UP amp NG A http idsc nih go jp index 1 html
159. TRPV1 TRPV1 SP AA CGRP CGRP SP TRPV1 SP TUE TRPV1 SP 4 SATE NO nNOS TRPV1 AAS E
160. ar THz MEE swimming climbing SMNaOH n hexane CH OH 0 05 6 ZT HPLC UV FST climbing 1 BVT in 39 0 EDN a MAID DAT 44 FST NA
161. 10 4 8 9 11 1 5 2005 2001 1 4 8 9 11 1 5 2
162. 2 3 6 HHV 6 1500mm 1 11000 mm HHV 6 B Tell 2 38 REV DIHS 100 HHV 6 IgG 1 HHV 6 IgG HHV 6 FE HHV 6 DHHS
163. gt iC NEA TER 150 Ocm TER 1000 Q cm 935 O cm ING aii
164. ycg7 c di GMP c di GMP yedT 2 3 yedT di guanylate cyclase yc27 D353N ycg7 YcdT yc7 Cyclic di GMP as a second messenger Current Opinion in Microbiology 9 218 228 2006
165. 1 2 3 PAR B WARNE HD 8 3 2 1 44 E 2 AE 4
166. BX 30 60 HEN LAU 8 FE HD RAE 6 Vol 51 FT es 22227 e EE e ge 2 e oc E 1998 400nm 1mL 12 5 0 01M 2011 PC2006 063 FOS
167. PFK LDH PDC MCT1 MCT4 2011 PC2006 091 ARI
168. f 4 E 4 E Ai Luros Ai Luros Ai Luros 4
169. 100g 5 30mg gt ax 2011 PC2006 098 D BH LPL amp Bi Bi2 Bu2 D D
170. 3 E 41 il 5 Lo ensing 56 81 86 2003 Macrolide antibiotic mediated downregulation of MexAB OprM efflux pump expression in Pseudomonas aeruginosa Anitimicrob Agents Chemother 52 4141 4144 2008 5 3 4 RT FEE PC2006 186 aA 3 ar 8 8 2008 360 TAZ PIPC 1 9 8 TAZ PIPC 2001 4 4 TAZ PIPC 1 8
171. LCST LCST LCST 5 85 N NIPAM Poly NIPAM 32 Poly NIPAM Poly NIPAM Poly NIPAM
172. a Table 1 Table 2 Excel Table 2 Missing Table 2
173. 2011 PC2006 033 1 2 0 8 EPA996mg DHA426ms student AA EPA AA EPA 1 01mol 8 5 47 1 1 61
174. compound 1 compound 2 1548 356 mg ODS flash CC HO MeOH 1 ODS TLC compound 1 fr 8H 27mg fr 8H NMR compound 1 7 citrifolia ursolic acid fr 8H compound 1 ursolic acid TLC Rf ursolic acid H HU C NMR PGE Hist compound 1 ursolic acid COX fr 8D 25 mg silica gel flash CC compound 2 9 mg
175. D 19 D 20 3 PURESYSTEM D 20 20 MSQYIADRK MNTHVFERK MCLWGPGRK 3 3 19 DNA IT PCR
176. j LPQ hybridoma PMRI 7 7 4 7 A 15 FBS 1 LPQO LPQ 8 3 5 RE nH BRK les LPQ vivo in vivo 1 ED ELISA 1 Transplantation Vol 77 10 1595 1603 2004 FW LPO EMO 52kDa 25SkDa
177. 3 2 PC2006 104 50 LDso H 1 1 900mg 1 1 502mg m 1 E 2 1
178. EF ZAM 1 2 MDRP RANE F Kiser University Teaching Hospital 108 58 MDRP THO FW 50 non MDRP MDRP 64 non MDRP 2 OprM MDRP 64 mexR 26 T mexZ OprM
179. IPS 0 1 60 2 LID LID AD 30 60 LTD LID AD JUN 1 0mA 8 8 3 LTD 1598 4 50 2 129 09 51 73 wu g cm2 IPS Cig RR
180. 6 g 6 1 600 1 1 0 6 6 1 1 2 Cm 2 n receiver CM V n n 1 Cm 50mgmL 75um 1 77 cm2 receiver 1 47mL h 5 74mL h 8 1 47mL h 5 74mL h 8 12 37ug cm2 23 05ug cm2 2 1 85 95ng7cm2 31 22ug cm2 2 7 E 28
181. Poly NIPAM 100 mg 10 mg MeOH 1 ml 40 gD 6 ml 1 5 ml 2 UV 234 nm 3 ml 0 5 ml 6 0 5 ml 3 ml 0 5 ml 6 1 6
182. ycg7 di guanylate cyclase yc77 D353A ycg7 D353N YcdT RK ycg7 0 3 15 80 yedT 130 IPTG 2 3 IPTG ycg7 yedT
183. HER 22 Fig Fig gt Ss hh i
184. TRPV1 2 TRPV1 383 DSS 3 4 DSS 4 REVEL TRPV1 7 8 7 ABC TRPV1 5 HT keratin TNF a substance P SP TNF a SP 5 HT SP OLYMPUS FV1000 ik 1 1 46900 47 27 MENTAA E 15 60mmHg
185. ee A AN 207 5 0 3 4 E VRE 7 4 1 Ea 3 C AUC Hark An 3 5 RE A H Zp 21
186. polyphenolic phytoalexin Cadenas Barja Resveratrol E C Resveratrol Resveratrol Resveratrol vitro Caddeo Resveratrol Resveratrol
187. CM HX f OTC 1 1461 1464 2009 62 623 626 2010 1 No 209 61
188. pETEREC Esherishia E BL21 Gen X 2xYT M9 1L 80 His TrapTM HP Al 30 000xG IPTG 0 5 mM 4 000xG 56 gt apTMHP GE Hearth care His Tag 4 HRV3C pET3CPRO coliRossetta His Trap HP His His TrapTM HP Imidazole 0 10 20 50 mM 4 TImidazole 0mM His Tag
189. 400nm gt Cas 3 7 7 a BSA BCA vvo 9 ARE hE HH mL 0 34gmL 0 15 80 60 120 BEX in vitro BRM LU i iH in vivo 5 0 GW 09 4 2 6 25mL EDR 30 TR
190. HDL Fig 1 2 1 HDL HR HDL HDL 70 mg dl HDL Fig 1 LEE HDL HDL Fig 2 v BMI HDL HDL Figl 1 a AI SHNA 0 Fig 3 5 Yr Risk of Major Cardiov
191. IPS receiver In vitro I Pr IPS 1 SBIR 2 HUN PVA LID PVA LTID AD Franz In vitro 60 4 LID AD 1 10 10 PVA SR 2 8mA 10 SH 30 2
192. PC2006 053 in vitro in vivo BE l 1 E aks ec 1 1 EAD EMR e
193. SR PSQI QD PSQ PSQI 2011 PC2006
194. 0 120 TRPV1 0 13COs 13COs 0 03 mg kg 2 0 3 mg kg 13CO2 3 0 mg kg CH as 5 TRPV1 ARR AER AULT gt Bs 1 1 ATES FUN TRPV1
195. 2011 PC2006 180 OTC FED 3 ES OTC Dis
196. ECT KES hm LXE ls o MMAR EER TCS 6 GE AE GE http fwww mhlw go jp stf shingi 2r985200000105vx att 2r985200000106er pdf 2011 PC2006 158
197. 20 HES E 20 2 8 21 Bligh amp Dyer 20 EPA 996mg day i HEL NEMEC UT 2 diheptadecanol sn glycero phosphocholin Avanti Polar Lipids Inc ALUSA DB 225 GC 2014
198. 530 110 50 240 GFP UL TE E GFP 020 ie 50
199. Sclafani MULTI FILT 2 F FLiE Donor Q ug V mL receiver F mL h receiver Tu ug receiver Cm ug Tu 1 t receiver ke CF V as he 79 dt dt t 0 Cw Co Cu 9 1 6 00 68 gt 1 6 1 Ke
200. 5 100 39 349 354 2003 CDC 2002 2005 PC2006 128
201. 1 Rng EBM CM 4 FA E
202. 37C 95 O 59 CO 2 Transwell 60 mm dish 4 109 FBS Milli Cell ERS XL 2 TER TER 1000 Q cm ZN
203. 7 0 yi NNN 60 3 1 70 2 1 Oral bisphosphonates and risk of cancer of oesophagus stomach and colorectum case
204. MAR 10 4 IF HP 3 4 9 3 0 15 70
205. 2011 PC2006 189 TRPV1 TRPA1 TRPV1
206. D 1wt BtOH 30mL 60wt KOH 15mL 70 15g 1 1wt NaCl 57mL n 1 9v y 45mL 2 MtOH 9 1v3mL HPLC Column YMC Pack ODS A 4 6mmi d x150mm Mobile phase CH3CN 011301 80 20Flow rate 1 0mL min Temperature 35C Detection UV254nm D Acetone EtOH
207. GF DZP ALA OKC Heme DZP GF DZP EtOH ALA Heme CP ALA EtOH
208. Histag His Trap SDS PAGE 25 kD 300 mM SDS PAGE 16 kD 37 kD 25 kD 37 kD His Tag B 16 kD His Tag 25 kD 6 me SDS PAGE 99
209. 10 mM MT TRPA1 SD 6 8 60 mg kg ip 1 95 g kg ip ex vivo 2 mg kg iv 950 nm TRPA1 HC 030031 28 16 mM 20 0 33 30 mM 50 mM 10 mM 8
210. 90 BMI85th percentile 2011 PC2006 204 2
211. BMI2 85th percentile Excel EVE JUN
212. NE BE MMT BORE FES SD SHR
213. R 0 92 P lt 0 01 Hig 1 g ew 2 5 51 1 3 0 5 gt Az 2 0 0 0 5 1 1 5 Rate of HH formation nmol min mg protein Fig l Correlation between M1 formation and HH formation in individual human liver cytosol MI HH 2011 PC2006 032 BlHHHHHHHHHHHHHHHHHHHI HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHH HH HHHHH HHHHHHHHHHHHHHHHHHH HHHHHHHH HHHHHHHH J BlHHHHH HHHHHHHH 0 0 0 0 0 8 0 0 OOH HHHHH HHHHH OOO OOO HHHHHHHHHHHHHHHHHHHHHHHH HHHHHUHHHHHHHHHHHHHHHHHHH BslHHHHHHHHUHHHHHHHUHHHHHHHHHHHH
214. MRSA VCM B 77 7 LAID 8 VCM MRSA MRSA 8 8 PBPenicillin binding protein MRSA 8 7 PBP2 8 PBP2 8 MRSA 8 PBP2
215. pH HW pH9 0 10 0 Hc 2 cox OH te LT 0 pH 35 pH pH pH xai Pica 3 24 HH E BATFE pH
216. 2011 A 20 4 1 ATU MEW 5 A Fn CAROL f REE Hic 1 2 5 gt EH HH 22 6 2
217. fractton2 LAE ROS 2 37 5 29 2 17 8 i 8 8 8 8 8 NO fraction2 2011 PC2006 122 HDL cholesterol LDL cho1estero LDL LDL gt 140 mg d1 HDL cholesterol HDL HDL gt 40 mg dl HDL
218. TRPA1 si HC 030031 10 mM TRPA1 120 30 mM TRPV1 TRPV1 TRPA1
219. E 4 6 1 13 15 c LRSA Otek 3 1 LRSA 2 23SrRNA 23SrRNA V 92 23SrRNA ES Clinical Outbreak of Linezolid Resistant Staphylococcus aureus in an Intensive Care Unit JAMA 303 2260 2264 2010 Resistance to Linezolid Is Mediated by the cfr Gene in the First Report of an Outbreak of Linezolid Resistant Staphylococcus aureus Clin Infect Dis 50 821 825 2010 PC2006 055 ycd7 nts
220. Ethanol 3 1 6 11 Ethanol Ethanol Saline Ethanol Ethanol Ethanol Ethanol Ethanol GABAA
221. pH C CF D DF fF FOS FOS FOS pH pH C CF D 5 DF EOS
222. 5mol OH oO O ae CH NO ir OzN 1 2 Ph Ph RHN NHR A H 42 8 ee R Me 66 44 ee Cu OAc z HzO A ON 4 Ph ph OH lt or ocOH 03S N__NPh pp Ph B C 23 25 ee R h 27 1 ee S 32 55 ee S BAA x 2011 PC2006 094 6 aza Wittig 1H Staudinger aza Wittig 5 2
223. A 5 2 6 5 1 PAN DR R 8 6 0 5 A 19 17 4 1 IM 0 27 ETC
224. E LPQNVWLHGWHT lk gt lt FITC ADSC SSV flow cytometry LPGQ ADSC CFSE ER flow cytometry ADSC CD29 CD44 CD90 CD83 CD29 ADSC 435 ADSC OME ACHES SSV 4 ADSC LPQ flow cytometry THE 9 CD45 LPQ SSV LPQ
225. OR 9 5 Crs ORpublished ORtotal data 1 MIX 1 7 EX Publication bias 95 P Odds ratio 95 Cl P value 1 17 0 91 1 51 0 216 115 Reboxetine v placebo Remission 1 17 0 91 to 1 51 Response 1 24 0 98 to 1 56 1 24 0 98 1 56 0 071 99 2 14 1 59 2 88 lt 0 001 25 2 21 1 45 3 37 lt 0 001 SSRls 0 80 0 67 to 0 96 Patients with adverse events 2 14 1 59 to 2 88 Withdrawal owing to adverse events 2 21 1 45 to 3 37 Reboxetine v SSRls Remission 0 80 0 67 to 0 96 0 80 0 67 to 0 95 Response 0 80 0 67 to 0 95 1 06 0 82 to 1 36 0 Patients with adverse events 1 06 0 8
226. gt AZ HH A H 4 g 2 RHE V F C Ahk POMS mas OAR EAR 3 1
227. 33 510 3 16 TAZPIPC 1 4 OMX CERT RR TAZ PIPC 80 0 TAZ PIPC 1 8 PIPC 32 49 45 8 LU ATLAS
228. 0 6g 1 0 J S Cone plate RE500L H RE500L 2 5C J S 48 R2 4 3 R1 4 3 83 9 575 19 15sec 70 60 120 1 600 Casson YS YSc ue D S Sc Casson FAME uc Casson D
229. 8 2006 1 2 5 mo ams 1 2 5 51 ons ca 2 390 0 2 5 2001 uy 457 E07 66 8 30 12 168 18 58 20 228 Ni HE dl GH 20058 anos an5z E487 8 OO 40 46 29
230. 1 1 5 BOSE OTC OTC 2 6 E OTC ROR 1 OTC OTC HE Em
231. MDRP HEI 2 EA AME oD ri
232. MacB GFP MacB H GRA LE AUR ATES A E 14 15 MacB LT Q TG1 pTH2023 OBW25113 pTH2023 MacB GFP GFP TG1 pTH1001 150 r min s0 110 170 240 GFP MacB FARE MAE CHE LEE CZ fi BC
233. 1000 mg kg 1 1000 mg kg 8 8 1 S TRPV1 5 HTs 4 8 TRPV 1 5 HT3 4
234. HHV 6 E T HHV 6 T 1 DIHS HHV 6 BEB 6 56 305 12 2010 2 6 EB HHV 4 HHV 7 DIHS CD4 T CD8
235. 4 SD 0 CZ C K KZ 4 1 78 Zn 1 Zn E AIN 93G C Zn K KZ Zn Zn 1 ERE WF HH KAEEIE MARZ BLD ROUTED 760 4576 0236 18 18 5 He 1 4 d0 dl4 Zn Zn ajMg ICP EX 4
236. 5 02 1 3 0 mg kg 1 0 mglkg 10 mg kg TRPV1 2011 PC2006 082 TRPA1 TRPA1 TRPA1 TRPV1
237. 5 FU 5 HTs f 5 FU 5 HTs NK 1 PC2006 201 f FER 4 QOL
238. Ai Luros Ai Luros Ai Luros Ai Luros 4 E Ai Luros Ai Luros Ai Luros Ai Luros Ai Luros E Ai Luros 2 EL
239. MTS assay DEX 10 9 10 8 107 106 105M BTC 5 CO2 6 24 48 106M DEX 37 5 CO 48 Cy8 Cy5 8 128 MTSassay DEX DREX 2 CyclinD3 Estrogen Receptor
240. 5 6 OOOOH 1IHHHUHHHHHHHHHUHHHHHHHI SHHHHHHHUHHHHHHHHHHHHHI 137 HH 741HHHHHHHHHHHHHHHHHHHHH 92 4 171 HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 5 1 1 211 38HH22 2H HH 2 43 29 49 28 7HHHHHHHHHHI HHHHH FTFQver3 0HHHHHHHHHHHH 93 5 HHHHHHHHHHHHHI HHHHHHHHHHHHHH22HHHHHHHHHHHHHHHHHHH HHHHH20liHHH PC2006 040 lp ol HE OO HHHHH IHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHUHHHHHHHHHHHHHHHHHHUHHHHHHH HHHHHHHHHHH HHHHHHTHHHHHHIHHHHHH 18SHHHHHHHHHH
241. 65 28 43 0 150 RN HbA1c RO eo 7 4 65 1 SU 5 8 6 1 3 1
242. 8 OC 1 8 1 tis SHR SHR sofdon BP98 A 3 24 1 6
243. hr mg 0 5 96 1 5 92 2 5 11 24 57 NMR 8 5 4ppm 2H 6 6 0ppm 1H 1 BAF Pi EAE 1 2007 AFT 11 E HHHHH20liHHH PC2006 013 HHHHHHHHHHHHHHHHHHHHHHHH
244. 1 http lwwwihyashibara co jplhtml press 2005 060525 index html 2 Dermatol Vol 197 771 775 1991 3 2008 242296 201 1 PC2006 057 BZ v 4 ee Donor 3 14cm2 Franz 1 H 0 1 0 3mA 8 ee Receiver 1 J FHA VRE HE LB EX 8 WFAOMYUERE FAA VA AN
245. Ni TUN Imidazole HRV3C 24 Imidazole SDS PAGE Imidazole 20 mM SDS PAGE 2011 PC2006 044
246. Mg 15 10kHz 20kHz 2011 PC2006 148 A
247. SSV LPQ 4 E SSV LPQNVWLHGWHT in vitro 5 Rj Jes E E h es in vitro in vivo Le E H1 LPQ 1 SSV LPQ A Dy
248. nm i E 1 x We 5 HT CHAT E nNOS 6 BEE CHE le 2011 PC2006 216 Big TBS
249. LID LAL LID LID AD E LID 2111 8 235 2 LID AD 30 60 MEE EOE PIE LID LID AD 520 3 74 0 731 82 98 0 g g 230 8 34 2 402 5 57 6 g g LID AD LID AD IPS LID 60 p lt 0 1
250. c di GMP 30 di guanylate cyclase GGDEF c di GMP ycg7 ycg7 DNA PCR ycg7 pTrc99A pTrc99A p206 2 Escherichia coli TG1 BW23S113 ycg7
251. 0 48 0 13 Hazard ratio Hazard ratio 95 CI el F 0 A Excel 3 EE 2011 PC2006 050 An Oral SA Tyrosine Kinase Syk Inhibitor for Rheumatoido Arthritis 1
252. 1 214 C t Fate por 100 000 ing scale 6 2009 2000 2004 1 11 4 10 7 11 2 50 yt 7 4 50 50 40 000 50 LU UW 1 1 50 E 40 AH ESATA 40 EE BE 40 3 3 bc pdf FLSA 2 FR nf x 2011 PC2006 018 1
253. K Hist 1 K fr3B OH fr3B TLC major spot fr 7F ODS flash CC MeOH H O 1 1 LH 20 MeOH spot gt 1 90 83 2 mg fr9E fr 7F 290 mg de ER 9E C1 1D rutin 53x10 g mL PGE M citorifolia MJ 1 5 PGE 0
254. HHV 6 3 5 gt 8 PC2006 114
255. 90 E 3 2 2 CEO BHR Es 2007 gt 0 59 E ANA 5 nz 7 3 55 1 ETE Fl Stage0 1 2008 2009 16 7
256. NDM 1 New Delhi metallo B lactamase OHS Klebsiella pneumonia Escherichia coli B B 2010 NDM 1 TV NDM 1 B B B B 6 NDM 1 X NDM 1 gt pET48b Xmal BamHl pETNDM1 N His Tag HRV3C pBTNDM1 BL21 GEN X M9 30C
257. 1 WBC SEG lt lt 2 FON WBC SEG 3 44 Clg TH 2 FE C f IFN 180pug H22
258. CD3 BrdU T Sug mL SSV mAb Sug mL SSV mAb Treg SSV BrdU BrdU 0 SSV mAb 2011 PC2006 141 A IPS 60
259. w Deoxo fluor 5 Me FICA Me ester 2 NMR 5 Me FICA Me ester 4 Me Deoxo fluor 5 Me 52 4 Me 92 Deoxo fluor 30 4 5 Me FICA Me ester 2 butanol al Pt C O ph pMeBr Os 1C 1 sh nanco 7 A Me Me HO CH MeOH COOMe COOMe 2 Butanol H3BO3 we Beoxotluor a n BuLi gt rar ie
260. Ethanol REthanol Ethanol Ethanol Al
261. FDA 52 246 FDA 8 Ca HET 15 B 1 AA Ca 2 EE IH je FDA Ca 152086 ARB Ca 20 91 AX X 33 H C 7 FDA C 17 C
262. GERD CGRP VAChT LOT E CGRP NO SP ACh Rt 2011 PC2006 017 pres TRPV1 FL TRPV1 gt transient receptor potential vanilloid receptor subtype1 TRPV1 0 TRPV1
263. SGs Fe AUF1 2 7 p37 p40 p42 045 GFP pEGFP HeLa DMEM RPM 100ng ml 2 42 30 3 anti PABP mouse anti p38MAPK rabbit TRITC TetramethylIrhodamine 5 and 6 isothiocyanate AUF1 TRITC FP free polysome CBP cytoskeleton binding polysome RPM FP RPM p37 p40
264. WARE ACR20 R788 150mg 100mg t 3 150mg 1 100mg1 2 ACR E x 2 H 3 PP x 2 2 0 gt t Tes x 2 R788 R788
265. 1 LPQ ELISA 2 64mg LPQ 2 64mg in vivo EYE in vivo in vitro 2 3mg MLR in vivo amp 2011 PC2006 134
266. 2 3 FIER AEH 1 2 2 Ez 5 LA 2 mM 617 0 33 1 773 3 37 5 745 4 28 9 30 1 652 2 25 8 E P A EPA Hit E PA EN EMD 7 3 LA3mM 8122 EPA 300mg TG300ms 1
267. 170 5cm IH 1 1 Nl 5 AST ALT oo C 65 4kg 16 40 4 C BNE 20 x25 I 35 a EK 22 9
268. 3 NA 1 RNA T Bs Dra 0 EHH Vol 54 No 10 1284 1291 2009 Vol 3 No 3 53 59 2002 7 2011 PC2006 119 AUF1
269. Ai Luros Luros Ai Luros Ai Luros Ai FE 10wt Ai Luros 1 gt 105 well Ai Luros
270. Es ma mo Dr EO Fa ls SS Er rE re os hey oo oo lees ns oer ons A Fer fora A sa lt casa arn pem pem re H F ET DDE 3 2 ee Oz OO 7 4 7 4 54 7 4 7 4 54 74 7 5 7 4 7 5 7 64 7 3 7 4 7 5 4 oO 54 54 64 TH oh 4 Sh pS SD EPP NSN NRE ESE EEE EE EE ERR PH a SS BSE 1 O_o 5 EE I 8 EAI EL om om mm
271. ICP Aw EET DRED EAR LORD AN HE FI EEL 7 6 gt 6 5725 LEI RAAF TIE ROE Zn mge 50g 15 4 3 5 3 15 1 05 0 Fl Fe F3 Fi Znmg 50g 6 8 1 3 9 0 C1 C2 C3 C4 C5
272. 10 RD 7579 FEF 7074 RD FERIA MD 65 69 60 64 55 59 50 54 45 49 40 44 7 35 39 30 34 25 29 20 24 0 1 40 30 20 10 10 20 30 0 20 Year Lag Time Between Smoking and Lung Cancer 4 000 3 500 3 000 2 500 2 000 1 500 1 000 500 3 o o WEEE AI 58 12 50 0 80 202 1 ty 0 4 85 ACO 2 H 7 18 30 an De eT 20 10 5 1950 55 60 65
273. 5 130020 VAAN 6 E6 10 a 2011 PC2006 047 BREE res AZ 2009 11 24
274. 1LT 9 5 5 Y Lz RROD 1 EA 2 7 Fo NB LTS 3 G PT EB 5 1 C 5 AF CHEE CR bh 4 EBA ORE Ais E As 0 1 4 Bl RL
275. p lt 0 1069 5 7 p 0 0735 p 0 0001 SJS 3 6 9 3 SIS 18 31 3 SIS 5 7 TAR SJS 0 68 1
276. 0 7mm 9 4 150 50560 10 KLHL SSV 500 L 50mSec 130V 10 2 SSV ELISA IP 2 IPS KLH SSV IPS 4 SSV IPS SSV MENEP 1H 500 KLH SSV Ss
277. 2010 2 4 860 NA Oe eR ep RD EY rE JS Ey NA 4 NA NA
278. 2011 PC2006 163 5 HT pap EOE CAPE FTE
279. 7 3 2 Xform NR JI U N 7 We b 2010 7 23 2010 8 9 R 5 1 50 500 NR 4 72 3 37 4 2 28 7
280. ARO lt 2 CC 1H noni ct Hi Pl EXD AO 1 noni specimen No SKP010003T MJ 1 HP 20 CO 2 1x10 gmL PGE EE fr 3B 140 g LH 20 CC MeOH HzO 3 1 fr7D 7F 107 1 gmL Es 12L 0 FRM ELT PGES EA Mie LT ENE PGE histamine Hist small scale fz MHL K MJ 1 12L FAA 7 El res C large scale
281. E E ROT
282. C57BL 6 TRPV1 TRPV1 ABC caltitonin gene related peptide CGRP substance P SP vesicular acetylcholine transporter VAChT neuronal nitric oxide synthase n NOS GERD 2 1 5 3 TRPV1
283. HP HP HP 0 WTF IF TH 2000 HP m3 com URL http www m3 com 43 HP oles
284. 1 K Sato etal J Pharm Sci 80 104 1991 AE 3A 2011 PC2008 058 EHR Ai AiLuroslt F polygonumyinctorium Luros 1 3 Ai Luros Ai Luros NO PGEs
285. PEER 1981 BED BEADNADX E Em MR 0 16 BCG
286. 1 10 1 Resverarrol Resveratrol 1 PBERNARD and J Y BERTHON Greentech S A Biopole Clermont Limagne 63360 Saint Beauzire Cedex France
287. 1 GI GI 1 GI GI RAFI COLE P 0 003 P 0 003 2 8 RAED ZA GI E TARE 5 E GI
288. 1 5 E E 2005 2006 2007 2008 2009 17 1 16 9 17 2 17 6 20 3 BLY 5 7 6 2 6 8 8 5 E A SWE amp HASH A 3A
289. 3 b Henry C 1 C 2 TADDOL
290. k CH3 H 5 2 BuLi PhPCls ee Buli EtNs 1 RTADDOL 29 ee 0 Menthol PhzPC1 BuLi 1 aza Wittig ee g TADDOL
291. GABAAo 1 1 Sandeep Kumar etal The role of GABAA receptors in the acute and chronic effects of ethanol a decade of progress 2009 DOI 10 1007 s00213 009 1562 z 2 Subhash C Pandey etal Brain Chromatin Remodeling A Nobel Mechanism of Alcoholism 2008 DOI 10 1523 INEUROSC1 5731 07 2008 4 AR 3A HH 2011 PC2006 025 f BEI
292. nNOS f TRPV1 NO VAChT TRPV1 VAChT VAOhT CGRP TRPVI TRPV1 GERD 4 GERD TRPV1 TRPV1 7 70
293. Zn Tukey Zn CZ KZ Zn Zn Mg KZ CZ Ca CZ KZ CZ KZA F Zn Mg Ca 3 Zn LEE KER Zn Peason r 0 83 p lt 0 01 Zn Zn AIN 93G Zn Zn Zn Zn
294. lt 1 0 RE UA AUC 3 ETTORE VANE E 9 PT 7602086 CEU CEU AUC AUC 11 3 2 1 8 1 1
295. 15 15 micro 2011 4 1 micro RNA micro RNA messenger RNAs messenger RNA micro RNA 14 messenger RNA 0 EOE
296. B 5 527 2 36 70 2 26 202077 86 7 2 6 amine amine amine 2011 PC2006 152 BA ElisabethinC ElisapterosinB Elisabethin C elisapterosin B Rodriguez
297. EE 9 10 14
298. Higure1 Ra OH Figurel i The Japanese Journal of Antibiotics 2005 51 p11 16 Malcolm P Page Curr Opin Pharmacol 2006 Vol6 p480 485 Phase LSD MRSA MRSA 2011 7 4
299. 0 5 ml 1 Poly NIPAM Poly NIPAM No 16 Page4 7 2006
300. E 20 4 500 xG 30 000 xG HisTrap HP Ni Imidazol H HH HiTrap 0 HP HH 2 mM HEPES 17 7 mg ml Hanging Drop 48x3 8 8L 36 24 mg SDS PAGE pH 1
301. IF 3 34 1 E 1 2 21 0721 0 18 21 85 7 85 76 17 21 080 9 0 2
302. mRNA PURESYSTEM Zp Tip MALDI TOE MS 9 1 D PURESYSTEM MALDI TOF MS L 1 A rn MSQYIADRK D
303. ne drs ET Bes
304. 8 52 582 1 708 p lt 0 05 17 12 RT PCR 3 HaCat shikonin p lt 0 05 PC2006 181 aes 14 as 508
305. GABAA w1 HDAC CS7BL 6J HE 6 11 2 g kg rota rod 11 vehicle TSA 2 6 vehicle TSA P2 GABAA 66 1 rota rod 1 1l
306. Protein Engineering Design amp Section vol 23 no 12 pp 947 954 2010 3 1 0 CDR 1 2 2 CDR 2011 PC2006 115 5 Coenzyme Q10 HAI Coenzyme Q10 CoQ10 10 CoQ10 Wrz
307. 545 HHV 7 DIHS 1 DIHS A 2 4 DIHS HHV 6 DIHS HHV DIHS 1 000 1 DIHS HHV 6 DIHS HHV 6 HHV 6 El DIHS 22 HHV 6 62 DIHS 38 RAE
308. E rH IDA E 60 25 PC2006 099
309. 96well night TT AX EE 96well PI plate Sug mL anti mouseCD3 100uL well MS T SSVmAb 2 10ug mL 100uL well 24hr 24hr T SSV H1 vitro EU in vivo SSV over 2X10cell mL 2 MS Treg 2 5 Xx 10 cell mL 100uL well 72hr SSV mAb CD3 1Shr BrdU mAb 1 2009 I
310. IPTG 0 5 mM 20C 15 5 4 000xG 30 000xG His Trap HP GE Hearth care SDS PAGE HRV3C 4C 24h 0 His Trap HRV3C NDM 1 His Trap E coli rosetta pET3CPRO 230 nm His Trap UV SDS PAGE 37 kD
311. LPQ CD29 CD44 CD90 1 ADSC Cs CFS CD45 ADSC 7 BIRICOWTHAE ELIZ 10 SSV 1 STEM CELLS 2007 25 818 827 EDS BE LPQ CD83 2011 PC2006 061 FE Sets bik l
312. 1 of ripe fruit juice of Morinda citrifolia Pacifichem 2010 Honolulu Hawaii Ea LH Hist CXF USB An rutin rutin BS lig z 2D NMR flavonoid Fc amp amp 2 DL M citriforia Hist 1 1 E Okuyama Y Tanaka D Watanabe et al Prostaglandin inhibitory components 2011 EF wal PC2006 066 1
313. 1 100 90 0 4 24 49 Al id 29 8 75 6 OTC 1 OTC 2 3 40 59 1 71 78 9 0TC 51 19 48 43 29 ul 4
314. 48 Resveratrol DPPC 1 PBERNARD and J Y BERTHON Greentech S A Biopole Clermont Limagne 63360 Saint Beauzire Cedex France ul 2
315. WN 2 3 2 3 30 DHE H AEE ER aH 1 7 0 25mg E 25mg E A 3 gt 1 0 2 1
316. HaCat shikonin HaCat AWH shikonin shikonin shikonin HaCat 6 well plate shikonin 40ng ml pH 6 8 DMEM 3 16 RNA Filgen
317. R p CN p NO m NO gt p Br p OCH p tBu p CN TLC HH K2CO3 CH OH HEN ANH ES EAA 38 ABH lk 3 1 hes 1 30 1 30 PTLC 30 TLC 11 NMR p 92 TLC 96
318. yyo CHEN 7 In vitro 1 v 49 12 1 HH 1 J Chromatogr B Vol 867 15 19 2008 2 J Chromatogr B Vol 821 8 14 2005 in vitro
319. 2 aza Wittig 0C BuLi PhsPCl aza Wittig 3 1 HPLO Staudinger dsc Ns 135 roc ee sn DMAP SMS 6 TF aze Witio lt CH CicH cl 2 9 menthol 2 Staudinger 0 Menthol BuLi PhsPO1 1 38 17 ee 80C 2 T
320. 2 5 5 1 24mol 3 39mol n 3 1 3 r 6 267 057 A EPA LZR EPA 2 8 HER CT 1 4 9 RIA ETL 18 20 EPA 2 4 JEO EPA 1 KOBAYASHI S HAMAZAKI T SAWAKI S and NAKAMURA H Reduction in the ADP release from shear stressed red blood cells by fish oil administration THROMBOSIS RESEARCH 65 3
321. 4 2011 PC2006 165 C C 1 100 C E ZH BA UN NEF DOE 47 1 C
322. 7 8 OH ao 0 JWPKR MK me 7 we MeO Me 6 Me _IMPKR 7 9 MeO Reagent a 2003 Mel b POCls DMF NH NH KOH c Na IAmOH HCI d pyrolidine Mel e NaH 5 iodo 2 butyne f PyHBrs DBU g PhsPMeBr tBuOK h Co COjs i NBS DBU j NaH 3 chloro 2 methylpropene agriblazeispirol C 1 2 6 Pauson Khand 1 6 8 1 M Hirotani et al Tetrahedron 2005 67 189 2 M Ishizaki et al Tetrahedron 2001 2Z 2729 2011 PC2006 067 4 AE AX
323. BREE 2 6 HER2 1 1 1mg kg 250ml 90 3 E 0 1 0 22 0 32 lt 1 0 5 3 1 0 1
324. 1 5 FU droxylase 1 TPH 1 serotonin transporter 11 00 17 00 vehicle 20 DMSO 5 FU 5 FU 400 mg kg 4 5 HT TPH 1 SERT 5 HTs 8P NK 1 control 5 FU 5 HT 5 FU 5 HT TPH 1
325. BC BC 64 mg kg BC 13CO F 5 90 5 009 60 mg kg 30 6 0 03 3 0 mg kg 0 03 30 mg kg 3 25 30 LENS gt 905 Os iN Ab Jed B33 rs wpe TRPV1 30 SR BC
326. E X FDA D A B 4 E E FDA
327. HHHHHHH nabumetone abumetone 6 methoxy 2 naphthylacetc acid 6 MNA HHHHHHHHHH6MNAHH 6HNAHHHHHHHH CYPI HHHHHH 6 hydroxy 2 naphthylacetic acid 6 HNA HHHHHHHHI IIHHHHHH 6 MNA HNAHHHHHH CYP2C11 CYP2C6 0 OO 0 cimetidine 2011 HHNADPHHHHHHHHHHHHHHHHH HHHHHHH cimetidine 50 nM 34 4 CYP2C11HH 40nLHHHHHHHHH6 MNA200maMHHHHH37 HHHH ncubate HHHHHHHH 40HHHHHHHHH 60H HHHHH 6HNAHHH HPLCH HHHHHHH naproxenHHHHHH HHHH6HNAHHHHHHHHUHHHHHUHHHH emegdine S0nMHHHUHHL L HHHHHHHHH 50 IHHHH 70 HHHHHHHHCYP2C1iHHHI HHHHHHHHHHHHHHI CYP2C6 CYP2C11 HHHHHH CYP2C1i 6HNAHIHHHHHHHHHHI 15HHHHHHHCYP2C11 CD HHHHHHHHHHHHHI HHHHHHHHHHHHHI HHHHHUHHH cimetidine 6 HNAI 61000126 CYP2C11 CYP2C6 HHCYP2CIIHHHHH
328. 160 T 2006 4 1 2006 6 30 3a 60 0 3b 86 ON NN 2 3b 3b
329. 37 2 17 0 30 mg kg p o TRPV1 BCTC 0 1mgkg sc EE TRPV1 TRPV 1 A
330. n WSc Y c D D Casson TOP2B 15 9 9 1 J S100 12sec J S200 23sec 1 0 S2sec J S1000 92sec J S2000 186sec J S100 3 8 5 2 28sec J S200 3 1 4 1 02sec T S500 4 24 0 75sec J S1000 7 3 6 0 61sec 71 1 82000 10 40 WT 0 27sec 5rp m 19 15 560
331. HF2 TRPV1 2 TRPV1 ddY 25 39g 2 600 mg kg ip 1 0 1 30 mg kg s c XM AEE 30 TRPV1 N 4 t Butylphenyl 4 3 chloropyridin 2 yl tetrahydoropyrazine 1 2H carboxamide BCTC 10 mg kg ip 90 0 3 100 mg kg p o 30
332. Ht 1 3 20 3 ARE 12 B 12 CE 20 42 2 EDTA 2K 3 2 30cm Sum 0 5ml Ht 30 4 t 5 1 r 37 5sec A 5 76 mPa s B 4 5 89 mPa s C 7 3 mPa s A C B C p lt 0 05 2
333. GC solution EPA EPA 1 AA EPA AA 0 14 0 39 2 51mol EPA AA 0 08 0 22 In 3 7 49mol1 10 23mol n 6 32 79mol 32 33mol In 3 9 053mol 11 72mol n 6 25 16mol 1 LOlmol D EH Los AIC 1 27 28mol IER JK EPA is A 1 RY 1 EPA 2 EPA 1 5g day Ge AHA
334. Leia TEE EE 3 17 3 2 9 Az 3 1 2 4 7
335. RRMARAEDY IF IF 3 4 a le fos 2 HP HP
336. 2011 PC2006 176 40 7 40 2 1 2009 40 2 gt nz 2004 4 60 40
337. 4 f lt 5 26 ZOE 5 2 7 1 350 DPB RF gt 0 DPB 1969 5 DATE FRE F 7 E A E A 5 ik 4 1 1 0 MexAB OpM 23363486 SND 6 0215 6 3 3 0 AI
338. pH EE pH j i E 8 pH RAMMED PHN 1 2011 PC2006 150 FSC 3
339. B56 MACS Column 10 FBS RPMI ARCA SE CoQ10 FACS 25SuM CoQ10 10 FBS RPMI CoQ10 25uM 12 SuM SuM 2 5uM CD83 CD83 CD45 HH FACS CoQ10 545 Fo RBIS VE CD83 0245 2SuMCoQ10 TLR
340. FE SD 150 300 g ex vivo Fz YAN CAEL mg ml 1 1 50 1 1 CTE 195 g kg ip 40 320 mg ml 10 50 80 320 TRPV1 15356 N 4 t Butylphenyl 4 3 chlorophridin 2 yl tetrahydropyrazine 1 2H carboxamide BCTC 2 7 mM mg kg iv 10 HID DER 40C 50C 320 mg ml 2 40 mg ml BCTC TRP ruthenium red TR
341. yfe4 Zi yfeA pTrc99A 1 co7z TG1 cg BW25113 ZOE yfeA TG1 TIPTG 0 01mM pTrc99A 47 Ja yz4 pTrc99A p206 pTrc99A p206 1 6 TG1 yz4
342. GTF 8 HC GF GF HC ALA 0 50 200 mg kg HC ALA CP 55940 CP HC CP GF 20 mg kg HC GF Bicuculline 3 mg kg 60 mg kg ip 5 CP 0 s C HC ALA200 3 Veh CP 0 0 HC Veh HC ALASO Pentobarbital GF CP CP HC 8H GF 10 ARF EZR RRA F OE ALA Ol 2 GF
343. HPLC D D HPLC D COE D28 8ug 30g 1 D HPLC D D 50g lpack 28 8 g OE 2011
344. 5 FU TPH 1 SERT SERT 3 2 SP 5 HTs 5 FU 5 HTs SP SP SP NK 1 5 FU NK 1 1 4 5 FU 5 HTs A GED LYN
345. A dx 43 SU AREAS SLVR Fig 1 B 6 623 DEAN 1 1 5 Fig 1
346. 83 A 20mol i ep a 8496ee 40 FLAT ABR 5196ee 3 19 19 ee 1b B E Me 2 Ve Me EtaN O MeCN a COOH Ml la 84 ee S Po O 3 a n b n 40 lb Sl ee S 45 4 1 55 2 96 KR 45 27 80 22 AJ en Me Me B B 10mol 18 45 ee 16 1b 16 ee
347. TG1 pTrc99A y4 TG1 1 4 LB IPTG TG1 pTrc99A 2 3 TG1 pTrc99A p206 ye4 TG1 pTrc99A p206 1 5 yye4 TG1 pTrc99A y4 2 5 TG1 pTrc99A p206 y4 2 8 4 TG1 pTrc99A p206 y4 2
348. E 1X 4 7 1 EEE 4 8 696 14364 A 6 6 20 3101 A 0 0005 107 1900 0 000027 1380 0 000043 1 237 5 0 007 1714 514 5414 American Journal of epidemiology Vol 148 No 11 E CDC 2 2 2004 8
349. mA 0 3mA B44 in vitro Receiver gt Passive 97 H 4 3A
350. By BATE AEE DACEPHEDNEROTE T 15 A HITC 8 f n AE AH ls A Rl
351. Imidazole Y E coli Gen X 2xYT es 20kDa Fi Nucleic Acids Research Vol 14 1986 p 4987 4999 Antimicrob Agents Chemother 2009 Vol 53 p 5046 5054 HRV3C His Tag 24 ACh 1H 1H NIA SDS PAGE Gen X M9 Gen X M9 i 46 kDa His Tag 14 kDa HRV3C 7 i 60 kDa SDS PAGE 20C 16
352. lh Oy PSQI 5 54 1 PSQI NN PSQI SRQ D MR 20 50 DO SRQ D PSQI SRQ D
353. 21 7 18 25 15 6 lt gt 5 BENT 24 FA EF R 55 FA ay WE PW FH 9 1237 1239 2010 2009 JGL2009 17
354. 90 83 85 LT
355. 23 77 Ex 225nm Em 350nm 20mL 30 4 100mL pH 3 54 0 pH 4 81 8 pH 5 89 69 pH 6 95 1 pH 7 90 8 pH 8 86 1 92 7 pH 5 6 3 40 3 pH 5 104 2 pH 6 99 2 106 1 1 6g
356. 5 1 A OA i H a ZF 4 ERR 5 D 6 TA
357. BERN LOEW 3 2 PEAR TIT in vivo 1 HH in vivo 2011 PC2006 004 HK BY 3
358. HP 43 5 22 512 IF BR 116 1 10 10 27 628 1 2 3 37 860 9 6 14 IF 9
359. KLH SSV 20mM pH8 5 1 57 mA 8 80 2 2 KLH SSV 100mM NaHCOs 1z gmL 96 BOLL 30 0 05 Tween20 PBST 3 3 1 BSA pH7 4 200L 1 PBST 3 PBST 1000 SOLLIMZ 1 PBST 3 Goat a amp mouse IgG Fc pAb HRP 50uLHN 1 PBST 3 2 2 Azino bis 3 ethyl benz
360. TNF a 4 E PC2006 078 13C af I MO 0 1 Bi Hel 9002 TRPV1 ddY 6 9 BC
361. MAD 12 2010 7 4 13 4 22 7 223 5 50 LDso Wr GCE 3 pH PC2006 084 2 BAO A E
362. T 31 P 73 8 barr large unilamellar vesicle LUV Bangham small unilamellar vesicle SUV Bangham CE
363. TRPA1 1 TRPV1 TRPA1 i E H 1 nM JE
364. TRPV1 5 HT keratin 5 HT EWA ERR LA DSS DSS8 TRPV1 BCTC 1 TRPV1 TRPV1 TRPV1 TRPV1 5 HT SP DSS 7 7000 1 DSS 1 50 4d lls TRPV1 5 HT SP TRPV1 5 HT SP 5 HT SP 5 HT SP
365. shikonin 2 2 1 shikonin 12 RNA RT PCR HaCat shikonin 2 2 1 Q 3 16 3 16 3 3 16 4 3 16 6 3 16 3 16 0 3 16 8 3 16
366. 13 4 22 1 223 6 3 BYU OK 3 PC2006 044 RAR 3
367. 2 OprJj OprM 100 8 8 MDRP mexR mexZ 92 12 13 nfxB mexZ 100 5 5 100 16 16 MDRP MIC 128ug mL 8 V 7 OX 7 35 ER MexAB OprM MexXY OprM Al OprM mexZ Maniati MIC 512pg mL amp
368. IPS IPS 5 IPS 1 TNakamura et al Transplantation 77 10 1595 2004 2 Kuei chen et al J Immunol 182 4283 2009 3 181 8 A 2011 4 8 2011 AiLuros QOL
369. 2 61 8 84 g SJS 1 SIS SJS 2 3 2 CK SIS 1 Roujeau J C et al Medication Use and The Risk of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis Engl J Med 333 1600 1607 1995 2011 PC2006 085
370. S bromo l indanone 33 S Br FICA 4 Me FICA S Me FICA 10 20 CDA 4 1 Ar FICA 2 hexanol neomenthol 0 02 0 05ppm FICA H NMR FICA 0 01 0 1ppm 2011 PC2006 159
371. Ex 225nm Em 350nm ODS 4 6 X250mm HU BHF 0 25mMpH6 03 7 0 25mM NaH2PO4 16 84 pH3 3 96 7 2 3 jw 81 9 1 3 5 67 5ngmL 1000ng mL y 689 61x 3664 0 9997
372. Excel 4603 RKTT AR N 4603 BMI lt 85th percentile BMI 85th percentile BML 95 BMI2 85th percentile i F 2
373. H1 Treg FH T Treg lt FA H f gt FK 506 binding protein i H1 HI 1 9 H1 Treg T H SSVLYGGPPSAA Treg
374. ddY 23 40 g 38C 95 0z 5 CO TRPA1 5 10 nM 100 TRPA1 H 2 7 all EOE amp 3 gt tv 15 GR
375. 1 in vitro in vivo 1 7 4 EAA REA AR AAR grafting 20 2000 E 5 CDR E coliDHS a cDNA 5 RACE I E 0 Superhumanization
376. 746bp 23SrRNA V 5 LRSA 4 LRSA ET E 5058 23SrRNA V 30S mRNA 50S fMet tRNA 70S MRSA 2008 E 23SrRNA V cfr BEL 2008 4 ICU LRSA ICU LRSA 15
377. FC EPEAT HAM 2 N hydroxy 4 oxo rifampicin rox DAH pColdl pColdrox BL21 DE3 Amp 2xYT 30 IPTG 0 5 mM 15 Ndel BamHl rox 3 E E rox rifampicin monooxygenase rox 2 farcinica VE l rox X
378. Mg Mg Mg Mg 1 PC 2 5W 2 20 10 10kHz 20kHz 90 180 L 10 20kHz 10kHz 2000Hz 30 180 CH L 10 9 10 3 2 5
379. PC2006 173 In BH GABAA 2 2g kg ip 1 1 1 6 11 1 6 11 Ethanol 2g k gs 11 8h
380. go om om gt 4 OT 2011H HHHH PC2006 187 HH HHHHH jHHHHHHHHHHHHH napumetoneHHHHHHHH nabumetone NAB HHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 6methoxy 2 napht acetic add 6 MNA HHHHHHHNABHHHHHHHOTHHHHHHHHHHH butanoneHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHH6CMNAHHHHHHHNABHHHHHHHHHHHHHH 4 6 methoxy 2 naphthyl butan 2 d M1 OOD 6CMNAHHHHHHHHH HHHHHHH M1HHHHHHHHHHHHHHHHNABHHHH 6CMNAHH HHHHHHHHHHHH Mido 6MNAHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI 6MNAHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHM1HH 6CMNAHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHH3Z CHHHHHHHHHHHHH 24HHH HH M1H Krebs Henseleit Buffer 1 0x106 37 C 60 COz incubator QO incubate incubateH naproxen acetonitrile HHHHHHHHHHHHHHHHHHHHHHH 10000xg 5 minHHHHHHHH HHHHHH 500ulHHHHHHHHHHHHHHHHexane Ethyl acetate 1 1H HHHHHHHHHHHHHHHHHHHHHHHHH 5mlHHHHHHHHH0 45 pu HHHHHHHHHHHH
381. RLRS NLRS Alum NLRS NALP3 1 J Immunology Vol 183 6186 6197 2009 2 46 1 61 65 2010 CoQ10 CoQ10 CoQ10 CoQ10 8 2011 PC2006 138 K
382. ald 5 HT SP TRPV1 TRPV1 keratin TRPV1 TRPV1 TNF a TNF a TRPV1 TRPV1 TRPV1 TNF a Bi E 5 HT SP TRPV1 TRPV1
383. lt C4 HSL MexR IL12 TNF a 3 E 6 AI ES The 1 DPB a DPB F i quorum s Japanese Journal of Antibiotics 360 MIC 100ug ml QS ANGE rls HH DPB
384. 2 Zn 4 Zn Zn E 35 281 1982 2011 EF PC2006 029 Morinda citrifolia L 1 Morinda citrifolia prostaglandin PG E histamine Hist
385. 4 4 SU Fl 2 SU Em 65 65 65 DPP 4 SU
386. GSH 2 L L 37 YM 100 5000 G 4 30 SDS PAGE 50 9 7 9 v 30 2 SYPRO Ruby Typhoon9200 DHFR DHFR GSH 2 S8H GSH 3
387. pH 25 C 3 1 2 3 Steven J Siegel et al Pharm Res 24 1919 2007 4 2011 PC2006 167
388. 8 ALA GF DZP DZP CR 5 30 35 s HOC CP 55940 CP ALA HC ALA 8 FUERA IE LORR AR Zot FUSER CIE Vehicle Veh DZP 5 mg kg po Srr 2 mg kg s c LORR Vehs DZP 2 mg kg p o EBIOH 4 g kg G p LORR EX 5 0 4 7 0025 CP A
389. FDA Briggs GG et al Drugs in Pregnancy and Lactation 8th ed Lippincott Williams amp Wilkins Philadelphia 2008 2011 PC2006 002 Bangham Fe BRA MERE J Ai Luros Bansham
390. 1 375860 A 3 95 mPa s B 3 92 mPa s C 4 23 mPa s CHO AEE Cf B C p lt 0 05 3 Ht A 48 1 B 48 1 CAE 49 4 4 Ht45 r 37 5sec A 5 23 mPa s B 6 09 mPa s C 6 31 mPa s A B A C p lt 0 0001 5 Ht45 1 375sec A 3 64 mPa s B 4 25 mPa s C 4 38 mPa s BEE CAE p lt 0 0001 6 ml 30sec A 0 549 mPa s B 0 971 mPa s C 0 932 mPa s A B A C p lt 0 0001 r 37 5sec r 375sec lt lt Ht lt
391. 2011 PC2006 205 AG LR MAE En OD 3936 LCT TORAID DDD 0 SIS Stevens Johnson syndrome SJS RT BED 1 5 DED SIS SIS 279 3 SIS 3 8 SIS
392. FST CYP2D6 NA climbing
393. n ni pak 1 6 f 3 n LEMAR Ark var 5 HT n NO
394. 5 6 MeMgBr 7 7 Dess Martin 2 Elisapterosin B 4 Dess Martin Grignard 8 40 48 8 Grubbs 8 4 2 8 3 ehisabethin C elisapterosin B 7 8
395. ALA i SA 6 RE 1s ER Je EOE GF gt BZ CA TEASER ORME ETAL CHE HC 5 5 Hii GF gt 2 0 1 mg kg 1 mg kg GF CP LR REAM ZATU Pentobarbital CP CP Bicuculline 4 7 CAL Fr EDD B ALA OF 1 ALA GF
396. E A E PA EPA 1 KOBAYASHI 5 IKUO T KEISUKE 5 TAKAHASHI 5 et al Effect of fish oil ingestion on RBC membrane function of a long distance runner in high altitude training J Lipid Nutrition 12 1 75 84 2003 2011 PC2006 046 it A 1 9
397. ERROR 207 5 as 13 4 re 21 ABE AUC 2 RE UVUAN C 2 EERE AUC 1 gt 1 0 2 A
398. eo7 BL21 DE3 qr AO X 5 PC2006 209 NDM 1 NDM 1 New Delhi metallo lactamase 1 NDM 1 7anpm 1 ezeC ereC pRT48b 00 0 al MSC PamHI
399. 2011 EE PC2006 215 MBM FMA A DEX DEX 0 1
400. 5 CI 25 Hiwatashi 1993 47 8 3 84 45 69 36 4 008 076 96 20 2 017 09 15 10 5 0 5 FFF FSFE FEE lt FPS FFF FF S lt lt 2011 PC2006 137 E 260 FET LTR gt USM 1 iia
401. 100mg R788 E BE 25 1 150mg H fF PP 0 05 P 0 05 E R788 150mg 100mg PC2006 081 H
402. 5 Oa rE as YE 5 as i 4 ODO 5 A SASS SEE Ar as 5 a no ase mm FO pm 9 0 OO ABCD BOY em OY ee PO Fes Oa 5 ae 0 0 ii EEN FAS GEN NN aE ES O oe SN 5 a 5 So oo oa 4 2 m ee esha el os as rsh uss arse an hoe rene en on con ana esos es nc
403. R cHo p 2 2 Ri Smol pp 24 HPLC A B A 1 a 2 b B 2 a
404. compound 2 H C NMR 2D NMR pomolic acid pomolic acid M citrifolia M citrifolia PGE Hist ursolic acid pomolic acid ursolic acid PGE Hist pomolic acid pomolic acid fr 4B
405. 4ab HPLC 4 lab 18 18 ee 149 1aJD H A B no O 4 a n 1 1 a n b n 2 bin NH 45 06 8 16 16 ee S 22 1 S gt Zlotin et al Russ Chem Rev 2009 78 737 3a 21 1a 3b 1b 88 8b 2011 PC2006 019 Agariblazeispirol C Agariblazeispirol C 1 Agaricus blaze 0 NG Cos CO a M
406. 5 Cyclic di GMP as a second messenger Current Opinion in Microbiology 9 218 228 2006 2011 PC2006 016 amp MRSA MRSA ES Madrid CE VY 6 LTI XS 5 2 1 2 cfr
407. C 2 o 5 136 27 FDA FDA ARTEL Ax 5 B C D D 1 FDA C D 19 JAR FTN DN MAE E 1 iC 16 1 FDA 14 EE
408. E A BB BEE C 5 mT
409. MiHHHH pmol min mg protein 1000 0 0 100 200 300 400 500 Cortisol pmol min mg protein Fig 1 Cortsol MIH EEE Dre pm Hg 3 ET 127 OCC COCO 1 OH LT oo oes os onc a rm oO gD LO m FRE o oO gg Emi eer EE Fees 3 m Oo 2s Nn En Sr bes 3 7
410. http www mhlw so jp topics bcg tp1107 1e html 2011 PC2006 142 19 3 XX 0 05 6 1987 ig 1 1987
411. 1 ik gt 1 0 E E URL http wwwr info pmda go jp shinyaku_index html 2 Accessed 2010 July 4 2011 PC2006 024 Al H1
412. 2 3 3 2 GI 3
413. HHHHH2O01iHHH HHHH PC2006 001 HH HHH IIHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH IIHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI IIHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI IIHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI IIHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI IIHHHHHHHHHHHHHHHHHHHHHHH 4 HHHHHHHHHHH 37 40mlHHHH4gHHHHHHHHHHHHHH 0 15 30HHHHHHHHHHHHHHHH 022 hm Millex IIUDUHHHHHHHHHHHHHHHHHHHHH 215 ml HPLCHHHHHH 0 5 10 15 20 25 30 35 DD OO wk 9 IIHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
414. PC2006 106 BH NR NR Web NR gt 7
415. EN ee dl ce 1 2 H 381 137 0 20 40 60 80 100 UE lt 3 3 58 gt Eh Eh LCTUIRUN D amp O ATT 1
416. Te oe 5 5 E 5mL 10mL 4 E 5mL 10mL 5 06mL 5 03mL JI 10mL 5 04mL 4 98mL JI 10mL 45 1 42 2 JI 10mL 35 6 18 0 JI rE Kf 4 J 10 a 1 a JI 2 3 2 EYEE RARE OER RAE DONTE 4 we 0 5
417. YfeA YfeA YfeA YfeA YfeA GGDEF EAL YfeA IPTG hasan ES E
418. mean SE H 10 10 42 8 10 6 mean SE L H 20 19 Mg Mg Mg 10kHz 20kHz 2 Mg Mg Mg
419. 207 6 4 DL 20814 5 2 572 6 Pe ALA 6 aminolevulinic acid griseofulvin GF FEE EFA EAE 02 AK DS 2 RB ml gt iC ICR 5 j 30 35 g 8536 4 0 8
420. 70 75 80 85 90 5 2 00 1820 25 30 35 40 45 50 55 80 85 70 75 80 85 30 95 2000 amp 3 2011 FARE PC2006 031 2 2 1 12 2 9 11 1 5
421. ER a 0 2 rH SE AE TRP TRPA1 30 800 mM 300 mM
422. GD gt BZy 7 Larsen TM Dalskov S Baak M et al 121068 with High or Low Protein Content and Glycemic Index for Weight Loss Maintenance New England Journal of Medcine 2010 363 2102 13 8 8 OE 26 1 4 1 Table 2 2 Table 3 P 0 012 2 4
423. HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 270 14 6 GrpilOD 3300 314 Grp2 TH OOO 350 29 7 Grmp3HHHHHHHHHHHHHH 22H 6HHH 12HHHH 6HHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHH 12H HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH A4HHHH 2HHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHH 12H HHHHHHHHHHHH2011 THHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHH ver3 0HHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHH 22HHHHHHHHHHHHHHHHHHH Grp2HHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHH 770HHH 46200562000 53 2HHHHHHHHHHHHHHGrp3HH 346 30 00HHHHHHHHHHHHHHHHHHHHHHGmlHHHHHHHHHHH Grp3HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHIHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHGm2HHHHH BsHHHHHHHHHHHHHHHH HHHHHGr3HHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH OO GrptlHHH Grp2HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 2011
424. Me 545 S Me FICA Me ester 4 Me FICA Me ester 5 3 methyl 1 mdanone 5 S Me FICA S Me FICA Me ester S Me FICA Me ester 2011 PC2006 101 0 PURESYSTEM D
425. SD 32 Ex 16 Sed 16 09 NaCl 25 8 CT n 8 CD 2ml 30 18 10 20 8 30 35 5 60 30 4 G STAT pH pCO2 BE 90 Tukey
426. gt 21 6 OTC Ar
427. 0 9 2 8 1 1 3 9 30 359 28 6 3 Ns 8 6 2 as 2 2 Eh 2011 0 PC2006 135
428. 0 gt 2011 PC2006 179 0 5 4 7 1 12 2 7 Av 2 j 49 3 10 4
429. 1 16 H 2 ER SR 2 EK ESE 77 3 5 30 5 NAH EAI OER
430. 1 E Bulbring et al J Pharmac Exp Ther 85 78 5 2011 PC2006 206 in vivo D H1 2 12 2 SSVLYGGPPSAA 4 Y Hl1 E LPQ LPQ SSV SSV
431. 1 0 HP IF 2 v
432. 159897 NO 100 nM A TRPA1 gt 15086 110030081 30 pM 100 nM 40 ATE FK888 10 pM NK2 gt ER SCA NK1 3 pM NO H L NAME 100 nM NO SEH L NAME NK1 NK2 NO 2011 7
433. 2 to 1 36 Withdrawal owing to adverse events PC2006 133 2 2
434. 4 7 6 0 2mL 10mL 5mL 1 006 1 3 E 10 5 4 18G 10 5mL 2 101 2 09mL 2 02mL 39 4 35 8 28 8 15 4 JI 1 5 RH
435. 5 HPV 1 ee 2 0 3 0 4 0 1 1 0 6 0 7 0 5 0 6 0 HPV E 1 0 5 0 5 JT 50 6 0 1 FE HDS Al 2 0 3 0 2 1 0 1 5
436. 53 364 1992 2011 PC2006 140 ZF J 8 100 200 500 1000 2000 Lot 5 AB Lot94025 Lot5118 9 1 0 0
437. 62 7 8 25 NR 94 7 94 68 45 6 19 1 6 60 6 57 4 S1 1
438. 71ug cmz2 25 68ug cm2 Sclafani Pharm Res 10 1993 0 2011 PC2006 151 1 1 1
439. AFH 1 5 NNN SERRE USN C gt 1 0 1 0 E BR 22 2 ERR VAN C gt 1 0 an 7 7 118 6088 C iE le PC2006 088 CO AUC JE KD gt 1 0 gt 1 0 C
440. ENEP micro emulsion 3 14cm2 SSV KLH SSV 650 gm 200 x L 1 2 5 0 314 mA 0 628 mA 1 570mA 380 E KLH SSV ELISA lt MENEP gt 1 00g I P 2 SSV 1 428 17 62g mL KLH SSVSOLL
441. FAK Y397 Phospho Specific 14 3 3 co CDC25C ErbB2 Y1248 Keratin20 CychnD3 Estrogen Receptor TrAK Y397 Phospho Specific 14 8 3 cg CDC25C CychnD83 Estrogen Receptor FAKY397 Phospho Specific 14 3 3 o CDC25C DEX ErbB2 Y1248 Keratin20 DEX 2 DEX
442. GI 2 GI RAFT E 5 1 5 6 gt PC2006 102 5 4 BH
443. HH HHHHHHHHUHHHHHHHHHHUHHUHHHHHHHHHHUH SOO HHHHHHHHHHHHHHHHHHHHHHH HHHHHHH HHHHHHHH HHHHHHHH HHHHHHHHHHHHH 7S0HX100HHHHHHHHH2 OO BslHHHHHH HHHHHHHHHUHHHHHHHIHHH3HHHHH 6HHI 1 1 1 1 1 98 HPLC HHHHHHHHHHHHHHHHHHHHH4GHHHHHHI 1 HHHUHHHHHHHHUHHHHHHUHHHH 3HHHHH4I 1 SHHHHHHHHHHHHHHHHHHHHHHHHI 1 1 HH 126HHHS71HHHHHHHHHHHI 90 96 DUI 100 58 86 Bl HHHHHHHH1HHHI HHHHHBsHHHHHHHHHHHHHHHHHHHHHHI AHHHHC 8 HH 1 2 3 4 5 HH HHHHHD WHHHHE HHH HH HHH 3H 6 00 5 HHHI HHHI HHHI Bl HH 0 5 PC2006 1HHHHHHH HHHHHHHHHUHHHHHHHHHHHHHHHHHHHHHHHHUHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
444. HHH 6HNAHHHHHHHHHHHHHH CYP2C11 0 0 ET EE ET EE ET CYP2CeHHHHHHHHH 6MNAHH 6 HNAHHHHHHHHHHHHHHI HHHHHHHHHHHHUHHHHHHH 6HNAHHHH LCYP2C11H CYP2C6 100 Fig l Inhibitory effects of cimetidine and antibody against CYP2C11 on 6 HNA formation in rat control naa S hepatic microsome 0 Each point represents the mean 50uM antibody 50uM antibody cimetidine cimetidine male female S D n 3 2011 FAA PC2006 008 K 1 5 4
445. HHH B HHHHUHHHHHHHHHUUHHHHHHHHHUHUHHHHHHHHHHHL BslHHHHHHHHHHHHHHHHHHHHHHUHUHHHUHUHHHHHHHH HHHHH 2011 HHHH FC2006 086 H HH HHHHH jHHHHHHHH HHHHH jIHHHHHHHHHHHHHHHHHH OOOOOOOOOOO HHHH HHHHHHUHHHHH nabumetoneHHHHHHHHHHHHUHHHHHHNabumetone HHHHHHH 4 6 methoxy 2 naphthyD butan 2 olM1H HHHHHHHHHUHHHHHHHHH HUHHHUHMIHHHHHHHHHHHH 6 hydroxy 2 naphthylacetic acid 6MNA H DO OO OOOO hydroxysteroid dehydrogenase 11B HSD 188 glycyrrhetinic acid nabumetone MIHHHHHHHHHHHHHHHHHHHHHHHUHHHHH7HHHHHHHHHHH HHHHHHHHHHHHHHHHHHH nabumetoneH MIHHHHHHHH 11B cortisone corsolHHHHHHHHHHHHHHHHHH nabumetone HB HSDHHHHHHHHHHHH HHHH NADPH HHHHHHHHHHHHH pH7 4 37 G 1 mM cortisone QQ 5 5 mM nabumetone cortisoneg 60 nabumetone 20 O HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHPLCHHHHHHHHHHHHH HHHHH HH cortsone cortisol nabumetone 1 1 HHHHHHHHHHHHHUHHHHHHHHHHHHHUHHHHH EgHHHHHH nabumetone MIHHHHHHHHHHH 11B HSDHHHHHHHHHHHHHHHH HH HH HH 0 5000 R 0 93 4000 20020 2000
446. HHHHHHHH HHHHHHUHHHHHHHHHHHHHHUHHHHHHHHHHHHHH 2011 HHHH PC2006 068 1 HH 0 HiHHHHHHHHHSHHHS0I IIHHHH 3 HHHHUHHHHHHHHHSHUHHHHHHHHHHHHHI IHHHHHHHHHEHHHHHHHHIHHHH3HHHHHHHHHHHHH HHHHHHHHHHH CM 21HHHHHUHHHHHHHHHHH HI HI OO HI 1 HH 1 1 OO 1 1 1 OO 1 70KIU L J 30kIOLHHHHHHHHHUUHHHHHHHHHHHI HUH30kOLHHHHHUHHHHHHHHUHHHHHHHHHI HHHHHUHHHHHHHHHHH3HHHHHHHHHHH70 1 1 HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI
447. HHHHHHHHHHHH 6CMNAHHHHHHH HPLC C18H MC Pack ODS A 5 mm 12 nm 150x4 6 mm 30 GOO 1 0 m min 20 mM KszHPO4 pH3 0 CHsCN 3 2H 280nmHHHHH 350nmHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHM1HHHHH 6 MNA 0 0 0 0 0 EE EE EE EA Ee 31 0 0 0 M 0 0 HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH6MNAHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHH 1 6MNAI EDS SE OE 3 CMNAH nmol min million cals 0 10 0 052 nmol min million cells mean 5 nS3 Q 1 39 5 8 nmol min million calls mean SD n 3 Q 6MNAHHHHHHHHHHHHHHHHHHHHHH HHHHH2O01ilH HHHH PC2006 210 1 HH HH HHHHHHHHHHHHHH nabumetoneHHHHHH 6 MNAHHHH 6
448. HHHHHHHHUHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 0 0 HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHUHHHHHHHHHHHHHUHHHHHHHHHHHHHHH HHHHHHUHHHHHHHHHHHHH 200 DHH HHHHHHHHHSHHH50OHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHUHHH 2HHHHHHH HHHHHHHHHHHHHHUHHHHHHHHHHHHH 4HHHH HHHHHHHHHHHHHHHHUHHHHHHHHHHHHHHHHHHHHHHHHHH 3 HHHHHHHHHH HHHHHHHHHHHHHHH 13 UIHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHSHHHHHHHHHHHHHHHHHHHHHHH HHHHHHUHHHHHHHHHHHHHHHHHHHHHHHHHHHH 4 HHHHHHHHHH HHHHHHHH3HHHH SHHHHHHHH HHHHHHCM 21HHHH HHHHHHHHHHHHHHHHHHH HHHHHHUHHHHH 3HHHHHHH HHH3HHHHH5HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHH3HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHH2KIOLHH 84KIOLHHHHHHHHHHHHUHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHUHHHHHHHHH HHHHHHHH3HHHHHHHUHHHHHHHH HHHHHHHHUHHHHHHHHH HHHHHHHHHHHHHHH nng OO 3 HHHHH 30 HH BIE KIU L n 2 78 50 KIU L 51 50 RE 34 39 48 00 RE 35 85 70 70 KIU L 30 KIU L 5 44 40 KIU L 29 87 KIU L 22 22 35 93 KIU L 19 08 30 n 33 16 91 KIU L 17 76 KIU L 5 03 18 18 KIU L 7 51 HHHHHHHHHHHHHHHHHHHHHHHHUHHHHHHHHHHUHHHHHHHHH HHHHHHHHHHHHHH HHHHHUHHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHUHHHHHHHHH HHHHHHH HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
449. HHHI HHHHHHHHHHHHHHHHHHHHH10HHHHOHHHHHHHHHHHHI UOC HHHHHHHHHHHHHH1SHHHH30HHHHHHHHHHHHHHHHH301 HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI 36 5 ON UN OR eNO HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH 30HI 10HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHI HHHHHHHHHHHHHHHHHHHHHHI 10 9 Fig 1IITIITIIIIHHHHHHHHH 7 HH 5 Open symbols 10 sec 5 4 sec R 0 77 3 9 2 Closed symbols 30 sec 30 sec R 0 83 0 2011 PC2006 005 5 4 6 methoxy 2 naphtyl butan 2 ol M1 M1 6 methoxy 2 naphthylacetic acid 6MNA Ml
450. LA REET CP DZP OLE BERTH RIE ALA Srr DZP OLE REHM CEP SERIE SRLS Srr Srr DZP ALA DZP LORR CP DZP EtOH Veh LORR CP EtOH ALA DZP ALA200 LORR E OH ALA50 AEC LORR ALA EtOH DZP
451. M Pauson Khand IMPKR 2 Pauson Khand hang Co CO 2 O A Co CO s Coz CO s Co CO 4L2 85 Me CO Me Me 2 6 3 3 20 C NaH 2 Wittig 5 6 Pauson Khand 46 91 8 8 6
452. P GGDEF EAL YegE PCR reg eg pTrc99A pTrc99A 206 regzZ DNA E coli TG1 PCR Prime STAR TAKARA TOPO eg PEC Profiling E coli Cromosome Ver 4 Gene Fasta Format GENTYX PCR yeg DNA 98C 60 s 55 5s DNA 70C 3 5min 30 PCR yegZ
453. PV1 40 0 50 40 320 mg ml AX 80 320 mg ml 80 mg m1l TRPV1 TRP ruthenium red 1 26 1 10 A mg ml 26C AOC 50 3 50C TRPV1 608
454. Pseudopterogorgia elisabethae Mycobacterium tuberculosis H37Rv 12 5ug mL 42 elisabethin O 79 elisapterosin B 1 2 Pauson Khand 8 3 elisabethin C elisapterosin B 1 Elisabethin C 1 3 4 m MCPBA TES 91 6 4 TES MCPBA 6 11 6 2 20
455. SF A549 RNA 8 CAM SDS PAGE 10 309 RXM Western blot SF2 ASF 14 1 9 TCA Western blot 1 BK RXM 05 51705 LPS A549 10 309 LPS micro RNA
456. Trc99A 206 pTrc99A YegE YegE YegE Cyclic di GMP as a second messenger Current Opinion in Microbiology 9 218 228 2006 PC2006 185 A E
457. ascular Events Fig 4 0 14 P lt 0 0001 0 12 FE 0 1 2 0 70 0 06 0 04 0 02 9 23535249 49 lt 5 50 lt 6 35 35639 40659 60669 70 lt HDLmgla 2 0s FOS neta 2 10 94 4 Hazard ratio 95 Cl versus Ql Q2 0 85 0 57 1 25 3 0 57 0 36 0 88 4 0 55 0 35 0 86 5 0 61 0 38 0 97 Ql 2 3 4 Qs gt 37 37 to lt 42 42 to lt 47 47 to lt 55 55 Quintile of HDL Cholesterol Level mg dl LDL 070 mg dl HDL HDL 1 Fig 3 TG HDL BMI TG RNR Fig 2 1 Fig 4 2 HDL mg al tes pecs pare pos 15 7 11 9 10 1 res 6 16601 6 63 0 60 7 58 2 1 Okamura Tet al Atherosclerosis 2006 184 143 150 2 Barter Pet al N Engl J Med 2007 357 1301 10 2011 PC2006 132
458. cohol induced tolerance and physical dependence in mice with ethanol insensitive 1 GABAA receptors Alcohol Clin Exp Res 2009February 33 2 289 299 doi 1111 j 1530 0277 2008 00832 x 2011 PC2006 175 4 5 1 EAR 9 OW ORE E
459. control analysis within a UK primary care cohort BMJ 2010 341 c4444 doi 10 1136 bmj c4444 Published 2 September 2010 Table 1 Excel P Table 2 P P Table 2 al et
460. e E complementarity determining region TNF 10 Resurfacing Complementarity determiningregion CDR 3 2 FH 1 CDR H1
461. g 10ml 4C 3000rpm 15 JE HPLC in vitro 6mL hr CER LE 200zL inviro UPLC Waters i EE 1 Cmax 0 1mg kg 10 Ing mL
462. g o FE 1 2 FAL FA in vitro in vivo FE in vitro 3 H ED H EH 4 w 0 01M p nitrophenyl D gl ucopyranoside e 400nm WNC y
463. i Luros Ai Luros Ai Luros 48h Ai Luros 10wt Ai Luros 2wt Ai Luros Ai Ai Ai Luros 1 http www hyashibara co
464. jp html press 2005 060525 index html 2 FRAGRANCE JURNAL 2006 9 3 Langmuir 2006 22 25343 2550 Preparation of Liposomes Using an Improved Supercritical Reverse Phase Evaporation Method 4 2008 242296 2011 PC2006 073 ay HI1 D SSV Keyhole Limpet Hemocyanin 500 KLH KLH SSV 2 3 14cm2 KLH SSV 9 160 650 g ml 200zL
465. othiazoline 6 sulufonic acid 50u LINZ 30 1 405nm CH KLH SSV 160 650 g ml 8 15 30 KLH SSV KLH SSV 3 KLH SSV 2 3 1 Kuei chen et al J Immunol 182 4283 2009 2 131 2011 4 pp 168
466. p42 p45 CBP S UTR TOP p42 p45 AUF1 RPM mRNA 02 8 3502 ELAT GFP AUF1 p37 p40 p42 p45 AUF1 SGs RPM p37 p40 AUF p42 p45 AUF1 508 p37 p40 p42 p45 RPM 3 UTR p37 p40 SGs S UTR TOP 7 p42 p45 RPM SGs
467. pH H E 1 P pH3 0 5 0 2HCI 1 CI pH pH pH pH pH a b a x Dmax xoamax Di E pH pH
468. racil 5 5 HT substance P SP NK 5 HT tryptophan hy SERT 5 HTs SP NK 1 C57 BL6J control FU 5 FU 5 FU 5p HTs
469. yf Resveratrol an original mechanism on tyrosinase inhibition International Journal of Cosmetic Science 22 219 226 2000 2011 PC2006 052 K H keyhole Li KLH SSV TPS iontophoresis micro needle electroporation lt IPS gt mpet Hemocyanin H 1105 SSV 2 SSV SSV 500 KLH M
Download Pdf Manuals
Related Search